PURPOSE: The conventional primary end point in trials of perioperative systemic therapy for muscle invasive bladder cancer is 5-year overall survival. We identified an association between disease-free survival at 2 to 3 years and 5-year overall survival. MATERIALS AND METHODS: We retrospectively analyzed a multicenter database containing records of 2,724 patients treated with radical cystectomy for muscle invasive bladder cancer with negative margins. Of these patients 844 had received adjuvant chemotherapy. We evaluated the association of disease-free survival at 2 and 3 years with overall survival at 5 years using Cox proportional hazards modeling and the kappa statistic. RESULTS: Overall 2-year/3-year disease-free survival was 0.63/0.57 and 5-year overall survival was 0.47. The overall agreement between 2-year disease-free survival and 5-year overall survival was 79%, and between 3-year disease-free survival and 5-year overall survival was 81%. Agreements were similar when analyzed within pathological substages, radical cystectomy decades and adjuvant chemotherapy subgroups. The kappa statistic was 0.57 (95% CI 0.53-0.60) for 2-year disease-free survival/5-year overall survival and 0.61 (95% CI 0.58-0.64) for 3-year disease-free survival/5-year overall survival, indicating moderate agreement. The hazard ratio for disease-free survival as a time dependent variable was 12.7 (95% CI 11.60-13.90), indicating a strong relationship between disease-free and overall survival. CONCLUSIONS: Disease-free survival rates at 2 and 3 years correlate with and are potential intermediate surrogates for 5-year overall survival in patients treated with radical cystectomy for muscle invasive bladder cancer regardless of adjuvant chemotherapy. These data warrant external validation and may expedite the development of adjuvant systemic therapy. In addition, they may be applicable to the neoadjuvant setting. Copyright Â
PURPOSE: The conventional primary end point in trials of perioperative systemic therapy for muscle invasive bladder cancer is 5-year overall survival. We identified an association between disease-free survival at 2 to 3 years and 5-year overall survival. MATERIALS AND METHODS: We retrospectively analyzed a multicenter database containing records of 2,724 patients treated with radical cystectomy for muscle invasive bladder cancer with negative margins. Of these patients 844 had received adjuvant chemotherapy. We evaluated the association of disease-free survival at 2 and 3 years with overall survival at 5 years using Cox proportional hazards modeling and the kappa statistic. RESULTS: Overall 2-year/3-year disease-free survival was 0.63/0.57 and 5-year overall survival was 0.47. The overall agreement between 2-year disease-free survival and 5-year overall survival was 79%, and between 3-year disease-free survival and 5-year overall survival was 81%. Agreements were similar when analyzed within pathological substages, radical cystectomy decades and adjuvant chemotherapy subgroups. The kappa statistic was 0.57 (95% CI 0.53-0.60) for 2-year disease-free survival/5-year overall survival and 0.61 (95% CI 0.58-0.64) for 3-year disease-free survival/5-year overall survival, indicating moderate agreement. The hazard ratio for disease-free survival as a time dependent variable was 12.7 (95% CI 11.60-13.90), indicating a strong relationship between disease-free and overall survival. CONCLUSIONS: Disease-free survival rates at 2 and 3 years correlate with and are potential intermediate surrogates for 5-year overall survival in patients treated with radical cystectomy for muscle invasive bladder cancer regardless of adjuvant chemotherapy. These data warrant external validation and may expedite the development of adjuvant systemic therapy. In addition, they may be applicable to the neoadjuvant setting. Copyright Â
Authors: Takehiro Iwata; Shoji Kimura; Beat Foerster; Nicola Fossati; Alberto Briganti; Pierre I Karakiewicz; Kilian M Gust; Shin Egawa; Yasutomo Nasu; Mohammad Abufaraj; Shahrokh F Shariat Journal: World J Urol Date: 2019-04-11 Impact factor: 4.226
Authors: Matthias May; Christian Stief; Sabine Brookman-May; Wolfgang Otto; Christian Gilfrich; Jan Roigas; Mario Zacharias; Wolf F Wieland; Hans-Martin Fritsche; Ferdinand Hofstädter; Maximilian Burger Journal: World J Urol Date: 2011-10-09 Impact factor: 4.226
Authors: Behfar Ehdaie; Alexandra Maschino; Shahrokh F Shariat; Jorge Rioja; Robert J Hamilton; William T Lowrance; Stephen A Poon; Hikmat A Al-Ahmadie; Harry W Herr Journal: J Urol Date: 2011-11-16 Impact factor: 7.450
Authors: Harun Fajkovic; Eugene K Cha; Evanguelos Xylinas; Michael Rink; Armin Pycha; Christian Seitz; Christian Bolenz; Allison Dunning; Giacomo Novara; Quoc-Dien Trinh; Pierre I Karakiewicz; Vitaly Margulis; Jay D Raman; Thomas J Walton; Shiro Baba; Joaquin Carballido; Wolfgang Otto; Francesco Montorsi; Yair Lotan; Wassim Kassouf; Hans-Martin Fritsche; Karim Bensalah; Richard Zigeuner; Douglas S Scherr; Guru Sonpavde; Morgan Roupret; Shahrokh F Shariat Journal: World J Urol Date: 2012-09-26 Impact factor: 4.226
Authors: William P Parker; Philip L Ho; Stephen A Boorjian; Jonathan J Melquist; Prabin Thapa; Jeffrey M Holzbeierlein; Igor Frank; Ashish M Kamat; Eugene K Lee Journal: World J Urol Date: 2016-03-04 Impact factor: 4.226
Authors: Jeffrey J Leow; Jens Bedke; Karim Chamie; Justin W Collins; Siamak Daneshmand; Petros Grivas; Axel Heidenreich; Edward M Messing; Trevor J Royce; Alexander I Sankin; Mark P Schoenberg; William U Shipley; Arnauld Villers; Jason A Efstathiou; Joaquim Bellmunt; Arnulf Stenzl Journal: World J Urol Date: 2019-01-25 Impact factor: 4.226